Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC
- None.
- None.
Insights
The collaboration between Haystack Oncology and Alliance Foundation Trials (AFT) represents a significant stride in the application of minimal residual disease (MRD) technology within oncology clinical trials. The utilization of Haystack MRD™, which is designed for highly sensitive circulating tumor DNA (ctDNA) analysis, could potentially revolutionize the way therapeutic responses are measured in cancer treatment. By providing detailed molecular insights, this technology can help in the early detection of cancer relapse, thus influencing treatment decisions and potentially improving patient outcomes.
MRD technology is a burgeoning field in cancer research and its integration into a phase II clinical trial for NSCLC is indicative of its growing importance. If the trial demonstrates that MRD technology can effectively gauge the efficacy of novel immunotherapy regimens, this could lead to broader adoption in clinical practice. Such advancements could alter the competitive landscape of the oncology diagnostics market, potentially benefiting Quest Diagnostics' position in the industry.
The integration of personalized MRD technology in evaluating the efficacy of atezolizumab and tiragolumab in NSCLC is a notable development. Atezolizumab, an anti-PD-L1 therapy and tiragolumab, an anti-TIGIT therapy, are part of a class of immunotherapies that have shown promise in treating various cancers by enhancing the immune system's ability to fight cancer cells. The combination of these drugs with chemoradiotherapy could potentially offer a more effective treatment protocol for patients with unresectable stage III NSCLC.
From a medical perspective, the trial's outcomes could have significant implications for patient care. Should the MRD technology prove to be a reliable predictor of treatment success, it could lead to more personalized and timely adjustments in therapy, ultimately improving survival rates and quality of life for patients with this challenging condition.
The strategic partnership between Haystack Oncology and AFT, supported by Genentech, is likely to be viewed positively by investors, given the potential for commercialization of new diagnostic tools and treatments for NSCLC. The success of the AFT-57 trial could lead to increased demand for Haystack MRD™, providing Quest Diagnostics with a new revenue stream and possibly leading to an uptick in the company's stock performance.
Furthermore, the pharmaceutical industry's increasing focus on precision medicine and personalized treatment approaches signals a shift towards therapies with higher efficacy and lower side effects, which could drive long-term growth for companies like Quest Diagnostics. However, investors should consider the inherent risks associated with clinical trials, including the possibility of negative results that could impact the perceived value of the MRD technology and the associated treatments.
"This research collaboration with AFT is a great opportunity to further explore the benefits of using highly sensitive and specific ctDNA analysis as a means to evaluate the efficacy of novel therapeutic approaches," said Dan Edelstein, Vice President and General Manager of Haystack Oncology. "Haystack MRD was purpose-built to detect ctDNA with unparalleled sensitivity, making it well-positioned to support the innovation of new treatment regimens."
"AFT is excited to work with Haystack Oncology to investigate promising new immunotherapy-based treatments in nationwide randomized cancer clinical trials," said David Kozono, MD, PhD, AFT Executive Officer and Alliance Immuno-Oncology Committee Co-Chair. "The new MRD technology, in conjunction with these novel therapies, offers a unique opportunity to significantly impact the lives of patients with inoperable locally advanced non-small cell lung cancer."
About Haystack Oncology
Haystack Oncology represents the culmination of over 20 years of technical and clinical development in liquid biopsy technologies by cancer genomics pioneers at Johns Hopkins School of Medicine. The company, a wholly owned subsidiary of Quest Diagnostics, developed Haystack MRD™, a next generation tumor informed approach for the measurement of minimal residual disease. Haystack MRD uses an error-corrected ctDNA technology to detect down to one ctDNA molecule in a million. Haystack Oncology works with biopharmaceutical companies to advance important therapeutics to global markets, from early phase clinical development to companion diagnostics. By detecting patients with measurable disease for enrollment, and helping to identify early treatment response and disease clearance as endpoints for treatment efficacy, Haystack Oncology can accelerate and improve the efficiency of clinical development programs. Haystack Oncology testing is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in
About Alliance Foundation Trials, LLC
Alliance Foundation Trials, LLC (AFT) is a research organization that develops and conducts cancer clinical trials, working closely with the Alliance for Clinical Trials in Oncology scientific investigators and institutional member network, research collaborators, and non-NCI funding sources. AFT seeks to fulfill the vision of the Alliance for Clinical Trials in Oncology to reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer. To learn more about AFT studies, visit AllianceFoundationTrials.org.
View original content to download multimedia:https://www.prnewswire.com/news-releases/haystack-oncology-and-alliance-foundation-trials-collaborate-to-use-haystack-mrd-technology-in-phase-ii-clinical-trial-for-unresectable-stage-iii-nsclc-302027787.html
SOURCE Quest Diagnostics
FAQ
What is the collaboration between Haystack Oncology and AFT about?
What is the purpose of the AFT-57 clinical trial?
Who is involved in the AFT-57 clinical trial collaboration?
What is the significance of the new MRD technology in the clinical trial?
Who are the key personnel involved in the collaboration?
